TMDX - Company ID 0001756262
The table below shows TransMedics Group, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $605.49M | $441.54M | $241.62M | $93.46M | $30.26M | $25.64M |
| Cost of revenue | $242.69M | $179.46M | $87.53M | $28.19M | $9.10M | $9.00M |
| Gross profit | $362.81M | $262.08M | $154.09M | $65.27M | $21.16M | $16.64M |
| R&D | $69.06M | $55.97M | $36.05M | $26.81M | $22.30M | $18.83M |
TransMedics Group, Inc. reported annual revenue of $605.49M for fiscal year 2025. That is up 37.1% from $441.54M in fiscal 2024. Over the 8 fiscal years shown, annual revenue grew from $13.02M (FY 2018) to $605.49M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $185.17M |
| $168.62M |
| $119.55M |
| $69.90M |
| $38.28M |
| $24.19M |
| Operating income | $108.58M | $37.50M | -$28.73M | -$31.44M | -$39.43M | -$26.38M |
| Income tax | -$82.77M | $316.00K | -$1.64M | $66.00K | - | $0.00 |
| Net income | $190.30M | $35.50M | -$25.00M | -$36.20M | -$44.20M | -$28.75M |
| EPS (diluted) | $4.87 | $1.01 | -$0.77 | -$1.23 | -$1.60 | -$1.16 |